Tetrachlorodecaoxide(Tetrachlorodecaoxide) - 药物靶点：CD163_在研适应症：炎症，过敏性鼻炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

TCDO、Tetrachlorodecaoxygen

+ [4]

靶点

CD163

作用机制

CD163抑制剂(富含半胱氨酸清道夫受体1型M130抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构-

非在研机构

Oxo Chemie(Thailand) Co.,LtdNuvo Research AG

最高研发阶段批准上市

首次获批日期

泰国 (1997-01-01),

炎症过敏性鼻炎

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

10

项与 Tetrachlorodecaoxide 相关的临床试验

TCTR20210604003 / Recruiting临床4期

An open-label split-face study of efficacy and safety of topical Timolol, topical Tetrachlorodecaoxide and topical Oxymetazoline on post comedo extraction facial erythema: a pilot study

开始日期2020-12-01

申办/合作机构-

ISRCTN12348610 / Completed临床2期

Effect of WF10 on hemoglobin A1c, neutrophil-lymphocyte ratio values and advanced glycation end product formation in type 2 diabetes mellitus patients with diabetic foot ulcers

开始日期2020-11-11

申办/合作机构-

NCT04372355 / Completed临床2期IIT

Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients

Study in adult Diabetes Mellitus patients with diabetic foot ulcers and elevated HbA1c who will receive standard wound treatment in combination with adjuvant therapy WF10 to compare the change of HbA1c levels at baseline and after treatment.

开始日期2019-06-19

申办/合作机构

Srinakharinwirot University

[+2]

100 项与 Tetrachlorodecaoxide 相关的临床结果

登录后查看更多信息

100 项与 Tetrachlorodecaoxide 相关的转化医学

登录后查看更多信息

100 项与 Tetrachlorodecaoxide 相关的专利（医药）

登录后查看更多信息

76

项与 Tetrachlorodecaoxide 相关的文献（医药）

2021-09-23·Evidence-Based Complementary and Alternative Medicine4区 · 医学

TCDO: A Community-Based Ontology for Integrative Representation and Analysis of Traditional Chinese Drugs and Their Properties

4区 · 医学

ArticleOA

作者: Liu, Lihong ; Lian, Chaojie ; Liu, Jing ; Gao, Bo ; Qiao, Xingchao ; He, Yongqun ; Zhu, Yan

Traditional Chinese drugs (TCDs) have been widely used in clinical practice in China and many other regions for thousands of years. Nowadays TCD’s bioactive ingredients and mechanisms of action are being identified. However, the lack of standardized terminologies or ontologies for the description of TCDs has hindered the interoperability and deep analysis of TCD knowledge and data. By aligning with the Basic Formal Ontology (BFO), an ISO-approved top-level ontology, we constructed a community-driven TCD ontology (TCDO) with the aim of supporting standardized TCD representation and integrated analysis. TCDO provides logical and textual definitions of TCDs, TCD categories, and the properties of TCDs (i.e., nature, flavor, toxicity, and channel tropism). More than 400 popular TCD decoction pieces (TCD-DPs) and Chinese medicinal materials (CMMs) are systematically represented. The logical TCD representation in TCDO supports computer-assisted reasoning and queries using tools such as Description Logic (DL) and SPARQL queries. Our statistical analysis of the knowledge represented in TCDO revealed scientific insights about TCDs. A total of 36 TCDs with medium or high toxicity are most densely distributed, primarily in Aconitum genus, Lamiids clade, and Fabids clade. TCD toxicity is mostly associated with the hot nature and pungent or bitter flavors and has liver, kidney, and spleen channel tropism. The three pairs of TCD flavor-nature associations (i.e., bitter-cold, pungent-warm, and sweet-neutral) were identified. The significance of these findings is discussed. TCDO has also been used to support the development of a web-based traditional Chinese medicine semantic annotation system that provides comprehensive annotation for individual TCDs. As a novel formal TCD ontology, TCDO lays out a strong foundation for more advanced TCD studies in the future.

2021-08-01·Plastic & Reconstructive Surgery2区 · 医学

Efficacy of Negative-Pressure Wound Therapy with Tetrachlorodecaoxygen-Anion Complex Instillation Compared with Standard Negative-Pressure Wound Therapy for Accelerated Wound Healing: A Prospective, Randomized, Controlled Trial

2区 · 医学

Article

作者: Sringkarawat, Sophilak ; Burusapat, Chairat

Background:Negative-pressure wound therapy (NPWT) with instillation is a novel wound therapy. The optimal solution is still being investigated. Tetrachlorodecaoxygen-anion complex (TCDO) causes increased phagocytosis and oxygenation. The authors’ objective was to investigate the efficacy of NPWT with TCDO instillation (NPWTi) and to compare the results with NPWT alone.Methods:A randomized controlled trial was conducted. Inclusion criteria were wound size greater than 4 cm2 and depth greater than 10 mm. Exclusion criteria were malignancy, immunocompromise, and allergy to TCDO. Patients were randomized into NPWT and NPWTi groups. Outcome measurements consisted of wound surface area, depth, volume, tissue culture, and pathologic evaluation.Results:A total of 24 patients in each group were enrolled. The percentages of wound surface area reduction of NPWTi and NPWT groups were 24.1 ± 6.8 and 28.2 ± 7.6 on day 12, and 19.0 ± 6.6 and 22.7 ± 7.8 on day 15, respectively (p < 0.05). The percentages of wound depth reduction were 16.4 ± 5.3 and 22.5 ± 10.5 on day 12, and 12.0 ± 6.7 and 14.1 ± 8.0 on day 15, respectively (p < 0.05). The percentages of wound volume reduction were 17.9 ± 4.6 and 21.6 ± 5.8 on day 12, and 14.7 ± 6.0 and 17.1 ± 6.6 on day 15, respectively (p < 0.05). No statistically significant difference in microbial reduction was found between the groups. Histopathologic examination showed that more angiogenesis was observed in the NPWTi group than in the NPWT group.Conclusions:NPWT with TCDO instillation statistically significantly accelerated wound healing, but it did not show significant microbial reduction. The authors’ results suggest that TCDO instillation may be an adjunctive treatment in NPWT.CLINICAL QUESTION/LEVEL OF EVIDENCE:Therapeutic, II.

2017-10-01·Addiction1区 · 医学

Assessing the impact of a temporary class drug order on ethylphenidate‐related infections among people who inject drugs in Lothian, Scotland: an interrupted time–series analysis

1区 · 医学

Article

作者: Joshi, Shruti ; Austin, Hannah ; Inverarity, Donald ; Yeung, Alan ; Sherval, Jim ; Morrison, Kirsty ; Ure, Roisin ; Henderson, Naomi ; McAuley, Andrew ; Weir, Amanda

AbstractBackground and AimsIn April 2015, the UK government enacted a temporary class drug order (TCDO) on ethylphenidate in response to reported harms associated with its use, in particular an outbreak of infections among people who inject drugs (PWID) in Lothian, Scotland. This study assesses the effect that the TCDO had on reducing the most common infections identified during the outbreak: Streptococcus pyogenes and Staphylococcus aureus.DesignThe outbreak was split into a pre‐intervention period (35 weeks) and a post‐intervention period (26 weeks) based around the date of the TCDO. Segmented negative binomial regression models were used to compare trends in weekly counts of infections between the pre‐ and post‐intervention periods.Setting and participantsPWID in the Lothian region of Scotland.MeasurementsCases of S. pyogenes and S. aureus infections reported within the National Health Service, Lothian.FindingsThere were 251 S. pyogenes and/or S. aureus infections recorded among 211 PWID between February 2014 and December 2015: 171 infections in the pre‐intervention period and 51 in the post‐intervention period. Significant trend changes in weekly S. pyogenes and/or S. aureus infections following the TCDO were found [relative risk (RR) = 0.88, 95% confidence interval (CI) = 0.82–0.94]. PWID who self‐reported using novel psychoactive substances (NPS) were at higher risk of acquiring these infections (RR = 1.81, 95% CI = 1.12–2.93), particularly when comparing the risk of infection with NPS use for a specific strain, S. pyogenes emm76.0, against the risk of infection with NPS use for S. pyogenes (emm types other than emm76.0) (RR = 3.49, 95% CI = 1.32–9.21).ConclusionsThe UK government's 2015 temporary class drug order on ethylphenidate was effective in reducing infections among people who inject drugs during an outbreak situation in Lothian, Scotland.

100 项与 Tetrachlorodecaoxide 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Tetrachlorodecaoxide	R	DB05389

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
炎症	泰国	-	1997-01-01
过敏性鼻炎	泰国	-	1997-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HIV感染	临床3期	美国	Nuvo Research AG	1999-11-02
HIV感染	临床1期	加拿大	Nuvo Research AG	1999-11-02
HIV感染	临床1期	美国	Nuvo Research AG	1999-11-02
过敏性鼻炎	药物发现	德国	Nuvo Research AG	2010-03-01
HIV感染	药物发现	加拿大	Nuvo Research AG	1999-11-02